Key Facts
- →Higher circulating C15:0 is associated with 22–38% lower type 2 diabetes risk across 33 studies and 95,810 people — but causality is not established
- →A 2026 Mendelian randomization study of 7,085 people found no genetic evidence that C15:0 causes cardiovascular benefit — the strongest test of causality available
- →Fatty15's core marketing claims — 'third essential fatty acid,' '3x better than omega-3s' — originate from company-funded research and are not recognized by any independent medical body
The Observational Signal Is Real
Multiple large independent cohort studies have found that people with higher circulating C15:0 levels have meaningfully lower rates of type 2 diabetes, cardiovascular markers, and metabolic syndrome. A 2020 meta-analysis of 33 prospective studies — 95,810 adults and 19,904 T2D cases — found a 22–38% lower T2D risk in the top versus bottom tertile of circulating C15:0. A 2025 European Heart Journal study found associations with lower ischemic heart disease risk in a Chinese cohort of 8,185 people. These associations are consistent and appear across independent research groups.
But Causality Has Not Been Established
Correlation is not causation — and in the case of C15:0, the mechanism for the association is almost certainly confounding. People with high circulating C15:0 also tend to eat more full-fat dairy, exercise more, smoke less, and have higher socioeconomic status. A 2026 Mendelian randomization analysis of the CARDIA and ARIC cohorts — ~7,085 U.S. adults — found no genetic evidence that C15:0 causes cardiovascular benefit. The authors explicitly concluded that C15:0 'functions as a biomarker of cardiometabolic health rather than a biologically active cardiovascular protectant.' The T2D signal is the strongest and most consistent; even there, the original meta-analysis authors state 'no definitive conclusions can be made until further investigation has been carried out.'
The 'Essential Fatty Acid' Claim Is Overclaimed
Fatty15 markets C15:0 as the 'third essential fatty acid' — alongside omega-3 and omega-6. This claim is not recognized by the National Academies of Science, Engineering, and Medicine, the FDA, or any independent dietary guideline body. Essentiality requires two criteria: that the body cannot produce it in meaningful amounts (plausible for C15:0), and that it is required for healthy physiological function (not established). OmegaQuant, a clinical fatty-acid testing laboratory with no financial stake in C15:0 supplements, identifies the second criterion as 'where the controversy lies.' A 2024 ScienceDirect review titles it a 'controversial essentiality.' 'Potential candidate for a newly described essential fatty acid' — the phrase used by the one research group that proposed it — is a long way from established fact.
The Conflict of Interest Problem
The majority of the clinically bold C15:0 research — including the foundational 2020 Scientific Reports paper, the '3x better than omega-3s' claim, and the 'Cellular Fragility Syndrome' framing — was authored or co-authored by Dr. Stephanie Venn-Watson. She is simultaneously the lead researcher on C15:0 health claims, the CEO of Seraphina Therapeutics, and the co-founder of Fatty15. She holds patents on C15:0 applications licensed to her own company. The '3x better than omega-3s' claim traces to a 2022 PLOS ONE in-vitro cell study comparing C15:0 to EPA alone — not to the full omega-3 system, not in humans, not in a clinical trial. No independent research group has replicated the foundational findings.
What the Human Trials Actually Show
As of mid-2026, only two randomized controlled trials of C15:0 supplementation exist. The primary Fatty15 human trial enrolled 30 participants aged 18–25 over 12 weeks and showed no significant cardiovascular changes on primary endpoints. The Center for Science in the Public Interest (CSPI) reviewed the evidence and concluded the clinical benefit claims are not supported. Major clinical guidelines from the American Heart Association, American College of Cardiology, and American Diabetes Association include no recommendation for C15:0 supplementation. The supplement is GRAS-classified and considered safe at the doses sold — but safety is not efficacy.
Can You Get Enough from Food?
C15:0 is found almost exclusively in the fat of dairy products, grass-fed ruminants (beef, lamb), and to a lesser extent fatty fish. The practical research target commonly cited is 200 mg/day — a midpoint, not a clinically validated threshold. A tablespoon of grass-fed butter delivers roughly 90–130 mg. An ounce of aged cheese delivers 50–130 mg. A 100g serving of fatty beef delivers 300–450 mg. Whether diet alone reaches 200 mg/day depends heavily on how much full-fat dairy you eat. The C15 IQ Calculator at c15iq.ingredientquery.com lets you estimate your personal intake from food and see how it compares. Note: all food C15:0 values are estimates with meaningful ranges — no per-serving figure should be read as precise.